Optomed

4.27 EUR

-1.27 %

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

5,358 following

-1.27%

+12.22%

-23.75%

-38.03%

+14.94%

+40.92%

-55.8%

-6.77%

www.optomed.com/investors

Optomed is a medical technology company. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that is resold under different brands. The company operates worldwide, with the largest presence in the Nordic market. The customers consist of research institutes and hospitals. Optomed is headquartered in Oulu.

P/E (adj.) (24e)

-17.59

EV/EBIT (adj.) (24e)

-16.44

P/B (24e)

3.49

Dividend yield-% (24e)

Target price

5.50 EUR

Recommendation

Buy

Updated

18.11.2024

NASDAQ Helsinki

OPTOMED

Daily low / high price

4.23 / 4.52 EUR

Market cap

84.09M EUR

Turnover

191.76K EUR

Volume

44K

Business risk

Valuation risk

Current

Juha Kinnunen

Analyst

Latest videos

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

02.12.2024

Health Technology & Pharmaceutical Developer Night – Tuesday, Dec. 13 at 4:00 pm EET

13.12.2022

Financial calendar

Annual report

13.02.2025

Interim report

06.05.2025

Interim report

07.08.2025

Interim report

06.11.2025

Income statement

	2020	2021	2022	2023	2024e	2025e	2026e	2027e
Revenue	13.0	14.9	14.7	15.1	15.0	20.2	27.5	34.7
growth-%	-13.1 %	14.1 %	-1.3 %	3.0 %	-0.4 %	34.5 %	35.7 %	26.3 %
EBITDA	-0.7	-2.0	-2.0	-1.8	-2.2	-1.1	4.0	8.6
EBIT (adj.)	-2.9	-4.8	-5.1	-3.7	-4.6	-4.2	-1.5	2.1
EBIT	-2.9	-4.8	-5.1	-4.0	-4.6	-4.2	-1.5	2.1
Profit before taxes	-3.2	-4.3	-5.6	-4.5	-4.7	-4.5	-1.7	1.8
Net income	-3.2	-4.2	-5.5	-4.4	-4.7	-4.5	-1.7	1.8
EPS (adj.)	-0.24	-0.31	-0.38	-0.25	-0.24	-0.23	-0.09	0.09
growth-%
Dividend	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend ratio

Profitability and return on capital

	2020	2021	2022	2023	2024e	2025e	2026e	2027e
EBITDA-%	-5.6 %	-13.5 %	-13.3 %	-11.8 %	-14.5 %	-5.2 %	14.7 %	24.8 %
EBIT-% (adj.)	-22.3 %	-32.2 %	-34.8 %	-24.3 %	-30.8 %	-21.0 %	-5.4 %	6.1 %
EBIT-%	-22.3 %	-32.2 %	-34.8 %	-26.3 %	-30.8 %	-21.0 %	-5.4 %	6.1 %
ROE	-14.9 %	-22.9 %	-29.3 %	-21.8 %	-21.3 %	-21.2 %	-9.4 %	9.9 %
ROI	-9.8 %	-18.9 %	-20.5 %	-15.5 %	-17.5 %	-16.0 %	-5.7 %	8.3 %

Valuation

	2020	2021	2022	2023	2024e	2025e	2026e	2027e
Share price (EUR)	7.10	9.80	3.75	3.72	4.27	4.27	4.27	4.27
Shares	13.3	13.6	16.2	17.8	19.3	19.3	19.3	19.3
Market cap	94.2	133.1	60.5	66.1	82.3	82.3	82.3	82.3
Enterprise value	90.1	133.3	57.3	62.4	76.2	83.2	86.1	85.7
EV/S	6.9	9.0	3.9	4.1	5.1	4.1	3.1	2.5
EV/EBITDA	-	-	-	-	-	-	21.4	10.0
EV/EBIT (adj.)	-	-	-	-	-	-	-	40.3
EV/EBIT	-	-	-	-	-	-	-	40.3
P/E (adj.)	-	-	-	-	-	-	-	45.8
P/E	-	-	-	-	-	-	-	45.8
P/B	4.7	7.8	3.0	3.2	3.5	4.3	4.7	4.3
P/S	7.2	9.0	4.1	4.4	5.5	4.1	3.0	2.4
Dividend yield
Equity ratio	64.6 %	58.8 %	65.0 %	70.0 %	72.3 %	63.1 %	52.5 %	50.2 %
Gearing ratio	-20.4 %	1.2 %	-16.0 %	-18.5 %	-26.2 %	4.3 %	21.9 %	17.7 %

Quarter data

	Q4/23	2023	Q1/24	Q2/24	Q3/24	Q4/24e	2024e	Q1/25e	Q2/25e
Revenue	3.7	15.1	3.3	3.5	3.1	5.1	15.0	4.1	4.8
EBITDA	-0.8	-1.8	-0.6	-1.2	-0.8	0.5	-2.2	-0.4	-0.2
EBIT	-1.3	-4.0	-1.2	-1.9	-1.4	-0.2	-4.6	-1.1	-1.0
Profit before taxes	-1.5	-4.5	-1.1	-1.8	-1.6	-0.2	-4.7	-1.2	-1.1
Net income	-1.5	-4.4	-1.1	-1.8	-1.6	-0.2	-4.7	-1.2	-1.1